JonesTrading Initiates Coverage On Prime Medicine with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Justin Walsh has initiated coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and a price target of $20.
September 06, 2023 | 8:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prime Medicine has been initiated with a Buy rating by JonesTrading, with a price target of $20.
The initiation of coverage by JonesTrading with a Buy rating and a price target of $20 indicates a positive outlook for Prime Medicine. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100